Salbutamol therapy in congenital myasthenic syndrome due to DOK7 mutation

详细信息    查看全文

• 作者：Paulo J. Lorenzoni ; Rosana H. Scola ; Cl¨¢udia S.K. Kay ; Luciane Filla ; Anna P.P. Mir ; a ; Jo?o M.R. Pinheiro ; Amina Chaouch ; Hanns Lochm¨¹ller ; Lineu C. Werneck
• 关键词：ADL-MG ; myasthenia gravis activities of daily living ; CMS ; congenital myasthenic syndromes ; Dok-7 CMS ; CMS related to Dok-7 deficiency ; QMG ; quantitative myasthenia gravis ; 6MWT ; 6  ; minute walk test
• 刊名：Journal of the Neurological Sciences
• 出版年：2013
• 出版时间：15 August, 2013
• 年：2013
• 卷：331
• 期：1-2
• 页码：155-157
• 全文大小：252 K

文摘

Introduction

Salbutamol is a selective B2-adrenergic agonist, which has previously been described to be associated with partial improvement of myasthenia gravis and congenital myasthenic syndromes (CMS). In this study, we analyzed the effect of salbutamol in five patients with Dok-7 CMS.

Methods

We studied 5 patients (2 male and 3 female), with a mean age of 27 ¡À 11.06 years, who harbored c.1124_1127dupTGCC, p.G64R and/or p.S45L mutations in DOK7 gene. Salbutamol was given at a dose of 2 mg three times daily (6 mg/day) to all patients. The response was assessed by QMG score at baseline, 3, 6, 9 and 12 months; ADL-MG score and 6 minute walk test at baseline and after 12 months during follow-up clinic visits. Side effect profile of salbutamol was also evaluated.

Results

We noted an increasingly positive response as measured by the QMG score after 3 months of salbutamol treatment. Improvement in specific subcomponents of the QMG score such as leg outstretched in 45¡ã supine was most marked. In ADL-MG scores and 6 minute walk test, comparison between baseline and after 12 months revealed a clear beneficial response. Salbutamol was well tolerated in all patients.

Conclusions

Salbutamol is an effective treatment in Dok-7 CMS. This study provides class IV evidence that salbutamol given at a dose 6 mg/day improves function as measured by the QMG score, ADL-MG score and 6 minute walk test.